Last reviewed · How we verify
Lurasidone 20, 40, 60, 80 mg, flexibly dosed
Lurasidone 20, 40, 60, 80 mg, flexibly dosed is a Atypical antipsychotic Small molecule drug developed by Sumitomo Pharma America, Inc.. It is currently in Phase 3 development for Schizophrenia, Bipolar I disorder depression. Also known as: Latuda.
Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain.
Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain. Used for Schizophrenia, Bipolar I disorder depression.
At a glance
| Generic name | Lurasidone 20, 40, 60, 80 mg, flexibly dosed |
|---|---|
| Also known as | Latuda |
| Sponsor | Sumitomo Pharma America, Inc. |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT7 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Lurasidone acts as an antagonist at dopamine D2 receptors and serotonin 5-HT7 receptors, with high binding affinity and selectivity for these targets. This dual mechanism helps regulate neurotransmitter activity implicated in psychotic and mood disorders. The drug has minimal affinity for histamine and muscarinic receptors, which may contribute to a favorable side-effect profile compared to older antipsychotics.
Approved indications
- Schizophrenia
- Bipolar I disorder depression
Common side effects
- Akathisia
- Somnolence
- Parkinsonism
- Nausea
- Headache
- Tremor
Key clinical trials
- A Phase III Study of SM-13496 in Patients With Bipolar I Depression. (PHASE3)
- Pediatric Open-Label Extension Study (PHASE3)
- Lurasidone Extended Use Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lurasidone 20, 40, 60, 80 mg, flexibly dosed CI brief — competitive landscape report
- Lurasidone 20, 40, 60, 80 mg, flexibly dosed updates RSS · CI watch RSS
- Sumitomo Pharma America, Inc. portfolio CI
Frequently asked questions about Lurasidone 20, 40, 60, 80 mg, flexibly dosed
What is Lurasidone 20, 40, 60, 80 mg, flexibly dosed?
How does Lurasidone 20, 40, 60, 80 mg, flexibly dosed work?
What is Lurasidone 20, 40, 60, 80 mg, flexibly dosed used for?
Who makes Lurasidone 20, 40, 60, 80 mg, flexibly dosed?
Is Lurasidone 20, 40, 60, 80 mg, flexibly dosed also known as anything else?
What drug class is Lurasidone 20, 40, 60, 80 mg, flexibly dosed in?
What development phase is Lurasidone 20, 40, 60, 80 mg, flexibly dosed in?
What are the side effects of Lurasidone 20, 40, 60, 80 mg, flexibly dosed?
What does Lurasidone 20, 40, 60, 80 mg, flexibly dosed target?
Related
- Drug class: All Atypical antipsychotic drugs
- Target: All drugs targeting Dopamine D2 receptor, Serotonin 5-HT7 receptor
- Manufacturer: Sumitomo Pharma America, Inc. — full pipeline
- Therapeutic area: All drugs in Psychiatry
- Indication: Drugs for Schizophrenia
- Indication: Drugs for Bipolar I disorder depression
- Also known as: Latuda